<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474695</url>
  </required_header>
  <id_info>
    <org_study_id>21441</org_study_id>
    <secondary_id>SEAGUL</secondary_id>
    <nct_id>NCT00474695</nct_id>
  </id_info>
  <brief_title>Study Evaluating Genotypes Using Lucentis</brief_title>
  <acronym>SEAGUL</acronym>
  <official_title>VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate whether the efficacy of Lucentis treatment for
      exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA
      polymorphisms
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment naive exudative AMD patients will receive Lucentis treatment as standard of care,
      and followed monthly for 12 months. Standard ophthalmologic exams will be performed, along
      with ETDRS visual acuity and optical coherence tomography (OCT). A blood sample will be
      obtained for DNA analysis. The primary outcome measure is change in visual acuity at 4 months
      after initial Lucentis treatment. Secondary outcomes are change in visual acuity and retinal
      thickness at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IND holder relocated from the University of Utah
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the VEGF and HTRA1 genotypes associated with improvement in visual acuity</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine VEGF and HTRA1 genotypes associated with change or no change in visual acuity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Age-Related Maculopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Active approved treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.05 mg intravitreal injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ranibizumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Moran Eye Center Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naive AMD patients;

          -  At least 50 years of age;

          -  Visual acuity between 20/40 and 20/320

        Exclusion Criteria:

          -  Pregnancy;

          -  Prior enrollment in a ranibizumab clinical trial;

          -  Previous therapy in either eye for AMD;

          -  Concurrent eye disease that could compromise visual acuity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bernstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Adventist Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Paul S. Bernstein</investigator_full_name>
    <investigator_title>Professor, Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Exudative age-related macular degeneration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

